# Seritage Growth Properties: financial statements, quarterly

SRG · NYSE · CIK 1628063 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/srg.md) · [Financials](/companies/srg/financials.md) · [Filings](/companies/srg/filings.md) · [Insiders](/companies/srg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/srg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.5](/filings/0000950170-24-125603.md) | [4.6 d](/filings/0000950170-25-047860.md) | [0.0](/filings/0000950170-25-072777.md) | [0.1](/filings/0000950170-25-108985.md) | [0.4](/filings/0001193125-25-283262.md) | [0.1 d](/filings/0001193125-26-134736.md) | [0.1](/filings/0001193125-26-224751.md) | [0.1](/filings/0001193125-26-352329.md) | [0.2](/filings/0001193125-25-283262.md) | [0.2 d](/filings/0001193125-26-134736.md) | [0.1](/filings/0001193125-26-224751.md) | [0.1](/filings/0001193125-26-352329.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [9.8](/filings/0000950170-24-125603.md) | [7.1 d](/filings/0000950170-25-047860.md) | [7.0](/filings/0000950170-25-072777.md) | [6.3](/filings/0000950170-25-108985.md) | [6.1](/filings/0001193125-25-283262.md) | [5.6 d](/filings/0001193125-26-134736.md) | [5.2](/filings/0001193125-26-224751.md) | [5.1](/filings/0001193125-26-352329.md) | [5.3](/filings/0001193125-25-283262.md) | [4.6 d](/filings/0001193125-26-134736.md) | [2.9](/filings/0001193125-26-224751.md) | [2.9](/filings/0001193125-26-352329.md) |
| Income tax | $m | [0.1](/filings/0000950170-24-125603.md) | [0.0 d](/filings/0000950170-25-047860.md) | [0.0](/filings/0000950170-25-072777.md) | [1.5](/filings/0000950170-25-108985.md) | [0.1](/filings/0001193125-25-283262.md) | [0.0 d](/filings/0001193125-26-134736.md) | [(0.2)](/filings/0001193125-26-224751.md) | [0.1](/filings/0001193125-26-352329.md) | [0.1](/filings/0001193125-25-283262.md) | [0.0 d](/filings/0001193125-26-134736.md) | [0.0](/filings/0001193125-26-224751.md) | [0.0](/filings/0001193125-26-352329.md) |
| Net income | $m | [(0.9)](/filings/0000950170-23-061211.md) | [3.7 d](/filings/0000950170-24-039550.md) | [(19.0)](/filings/0000950170-25-072777.md) | [(101)](/filings/0000950170-25-108985.md) | [(22.0)](/filings/0001193125-25-283262.md) | [(11.4) d](/filings/0001193125-26-134736.md) | [(22.2)](/filings/0001193125-26-224751.md) | [(28.5)](/filings/0001193125-26-352329.md) | [(12.4)](/filings/0001193125-25-283262.md) | [(5.1) d](/filings/0001193125-26-134736.md) | [(30.3)](/filings/0001193125-26-224751.md) | [(6.1)](/filings/0001193125-26-352329.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0000950170-24-125603.md) | not reported | [(0.36)](/filings/0000950170-25-072777.md) | [(1.82)](/filings/0000950170-25-108985.md) | [(0.41)](/filings/0001193125-25-283262.md) | not reported | [(0.42)](/filings/0001193125-26-224751.md) | [(0.53)](/filings/0001193125-26-352329.md) | [(0.24)](/filings/0001193125-25-283262.md) | not reported | [(0.56)](/filings/0001193125-26-224751.md) | [(0.13)](/filings/0001193125-26-352329.md) |
| Basic EPS | $ per share | [(0.04)](/filings/0000950170-24-125603.md) | not reported | [(0.36)](/filings/0000950170-25-072777.md) | [(1.82)](/filings/0000950170-25-108985.md) | [(0.41)](/filings/0001193125-25-283262.md) | not reported | [(0.42)](/filings/0001193125-26-224751.md) | [(0.53)](/filings/0001193125-26-352329.md) | [(0.24)](/filings/0001193125-25-283262.md) | not reported | [(0.56)](/filings/0001193125-26-224751.md) | [(0.13)](/filings/0001193125-26-352329.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: not reported
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [98.9](/filings/0000950170-24-125603.md) | [134](/filings/0001193125-26-134736.md) | [115](/filings/0000950170-25-072777.md) | [86.7](/filings/0000950170-25-108985.md) | [85.6](/filings/0001193125-25-283262.md) | [85.2](/filings/0001193125-26-352329.md) | [94.3](/filings/0001193125-26-224751.md) | [71.8](/filings/0001193125-26-352329.md) | [51.5](/filings/0001193125-25-283262.md) | [48.1](/filings/0001193125-26-352329.md) | [44.5](/filings/0001193125-26-224751.md) | [48.4](/filings/0001193125-26-352329.md) |
| Total assets | $m | [1,016](/filings/0000950170-23-061211.md) | [974](/filings/0000950170-25-047860.md) | [915](/filings/0000950170-24-057853.md) | [758](/filings/0000950170-24-097088.md) | [735](/filings/0000950170-24-125603.md) | [678](/filings/0001193125-26-134736.md) | [650](/filings/0000950170-25-072777.md) | [576](/filings/0000950170-25-108985.md) | [559](/filings/0001193125-25-283262.md) | [394](/filings/0001193125-26-352329.md) | [361](/filings/0001193125-26-224751.md) | [354](/filings/0001193125-26-352329.md) |
| Total liabilities | $m | [456](/filings/0000950170-23-061211.md) | [411](/filings/0000950170-25-047860.md) | [371](/filings/0000950170-24-057853.md) | [317](/filings/0000950170-24-097088.md) | [316](/filings/0000950170-24-125603.md) | [272](/filings/0001193125-26-134736.md) | [267](/filings/0000950170-25-072777.md) | [223](/filings/0000950170-25-108985.md) | [220](/filings/0001193125-25-283262.md) | [61.0](/filings/0001193125-26-352329.md) | [59.9](/filings/0001193125-26-224751.md) | [61.4](/filings/0001193125-26-352329.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [559](/filings/0000950170-23-061211.md) | [562](/filings/0000950170-25-047860.md) | [542](/filings/0000950170-24-057853.md) | [440](/filings/0000950170-24-097088.md) | [418](/filings/0000950170-24-125603.md) | [404](/filings/0001193125-26-134736.md) | [381](/filings/0000950170-25-072777.md) | [351](/filings/0000950170-25-108985.md) | [338](/filings/0001193125-25-283262.md) | [331](/filings/0001193125-26-352329.md) | [300](/filings/0001193125-26-224751.md) | [292](/filings/0001193125-26-352329.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.5) d](/filings/0000950170-24-125603.md) | [(11.0) d](/filings/0000950170-25-047860.md) | [(16.6)](/filings/0000950170-25-072777.md) | [(7.5) d](/filings/0000950170-25-108985.md) | [(15.5) d](/filings/0001193125-25-283262.md) | [(13.9) d](/filings/0001193125-26-134736.md) | [(9.2)](/filings/0001193125-26-224751.md) | [(12.0) d](/filings/0001193125-26-352329.md) | [(12.5) d](/filings/0001193125-25-283262.md) | [(1.2) d](/filings/0001193125-26-134736.md) | [(5.7)](/filings/0001193125-26-224751.md) | [(1.6) d](/filings/0001193125-26-352329.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q2 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [55.4](/filings/0000950170-23-061211.md) | [56.1](/filings/0000950170-24-057853.md) | [56.2](/filings/0000950170-24-097088.md) | [56.2](/filings/0000950170-24-125603.md) | [56.2](/filings/0000950170-25-072777.md) | [56.3](/filings/0000950170-25-108985.md) | [56.3](/filings/0001193125-25-283262.md) | [56.3](/filings/0001193125-26-224751.md) | [56.3](/filings/0001193125-26-352329.md) | [56.3](/filings/0001193125-25-283262.md) | [56.3](/filings/0001193125-26-224751.md) | [56.3](/filings/0001193125-26-352329.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.